Investigating the relationship between vitamin D levels and immune-mediated colitis

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Immune checkpoint inhibitors (ICIs) can trigger immune-mediated colitis (IMC).
• Vitamin D's role in immune regulation suggests a potential link to ICI-induced adverse events.
• Understanding this association is crucial for managing patients on ICI therapy.

Purpose of the Study:

• To investigate the association between serum vitamin D levels and the incidence and severity of IMC.
• To explore vitamin D supplementation as a potential intervention for IMC.

Main Methods:

• Retrospective single-center study of 179 patients treated with ICIs.
• Serum vitamin D levels were measured within 6 months of ICI treatment initiation.
• Patients were analyzed for the development and severity of IMC.

Main Results:

• Patients with vitamin D levels ≤40 ng/mL experienced more severe diarrhea (65.0%) and colitis (48.0%) compared to those with levels >40 ng/mL.
• Lower vitamin D levels (≤40 ng/mL) were associated with increased severity of IMC.
• Patients with severe IMC (grade ≥2) had significantly higher odds of requiring steroid treatment.

Conclusions:

• Serum vitamin D levels are associated with the severity of immune-mediated colitis.
• Vitamin D deficiency correlates with more severe IMC and a greater likelihood of requiring steroid therapy.
• Further research into vitamin D supplementation for IMC prevention or treatment is warranted.